US 11,963,950 B2
Formulations of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile
Mark Reynolds, Millbrae, CA (US); and Charles Todd Eary, Longmont, CO (US)
Assigned to Loxo Oncology Inc., Stamford, CT (US)
Filed by Loxo Oncology, Inc., Indianapolis, IN (US)
Filed on Nov. 18, 2021, as Appl. No. 17/530,019.
Application 17/001,793 is a division of application No. 16/156,903, filed on Oct. 10, 2018, granted, now 10,786,489.
Application 17/530,019 is a continuation of application No. 17/001,793, filed on Aug. 25, 2020.
Claims priority of provisional application 62/570,601, filed on Oct. 10, 2017.
Prior Publication US 2022/0087988 A1, Mar. 24, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/439 (2006.01); A61K 9/00 (2006.01); A61K 9/08 (2006.01); A61K 9/16 (2006.01); A61K 9/20 (2006.01); A61K 9/48 (2006.01); A61K 31/498 (2006.01); A61K 47/02 (2006.01); A61K 47/10 (2017.01); A61K 47/12 (2006.01); A61K 47/26 (2006.01); A61K 47/38 (2006.01); A61P 35/00 (2006.01)
CPC A61K 31/439 (2013.01) [A61K 9/0053 (2013.01); A61K 9/08 (2013.01); A61K 9/1611 (2013.01); A61K 9/1623 (2013.01); A61K 9/1641 (2013.01); A61K 9/1652 (2013.01); A61K 9/1682 (2013.01); A61K 9/2009 (2013.01); A61K 9/2018 (2013.01); A61K 9/2031 (2013.01); A61K 9/2054 (2013.01); A61K 9/4825 (2013.01); A61K 31/498 (2013.01); A61K 47/02 (2013.01); A61K 47/10 (2013.01); A61K 47/12 (2013.01); A61K 47/26 (2013.01); A61K 47/38 (2013.01); A61P 35/00 (2018.01)] 23 Claims
OG exemplary drawing
 
1. A solid formulation comprising a compound of Formula (I):

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt, amorphous form or polymorph form thereof, in an amount from about 20 wt % to about 50 wt % and one or more excipients.